lenalidomide has been researched along with Infection in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, CW; Eom, HS; Kang, HJ; Kim, I; Kim, JS; Kim, K; Kim, MK; Kim, SJ; Lee, HS; Lee, JJ; Lim, SN; Min, CK; Mun, YC; Shin, HJ; Suh, C; Yoon, DH; Yoon, SS | 1 |
| Sun, H; Ying, L; YinHui, T; Yunliang, Z | 1 |
| Aldaoud, A; Harde, J; Knauf, W; Losem, C; Mittermueller, J; Neise, M; Niemeier, B; Potthoff, K; Trarbach, T | 1 |
| Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, TW; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Lim, JY; Min, CK; Park, SS; Ryu, DB; Yoon, JH | 1 |
| Andersson, BS; Berenson, JR; Champlin, RE; Chang, VT; Guan, X; Qazilbash, MH; Shen, Y; Wang, J; Wang, ML; Wang, Y; Yang, F; Zhang, W | 1 |
| Chavez, JC; Dalia, S; Kharfan-Dabaja, MA; Komrokji, R; Lancet, J; Locke, FL; Nodzon, L; Pinilla-Ibarz, J; Piris-Villaespesa, M; Powers, J; Sokol, L; Sotomayor, EM; Turba, E | 1 |
| Harrison, SJ; Slavin, MA; Teh, BW; Thursky, KA; Worth, LJ | 1 |
| Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS | 1 |
| González RodrĂguez, AP | 1 |
| Caraffa, P; Caravita, T; de Fabritiis, P; Gentili, S; Leoni, P; Offidani, M; Perrotti, A; Siniscalchi, A | 1 |
| Badoux, XC; Burger, JA; Faderl, S; Ferrajoli, A; Keating, MJ; O'Brien, SM; Sargent, R; Wen, S; Wierda, WG | 1 |
4 review(s) available for lenalidomide and Infection
| Article | Year |
|---|---|
Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Humans; Immunologic Factors; Incidence; Infections; Lenalidomide; Mortality; Multiple Myeloma; Publication Bias; Risk; Severity of Illness Index; Thalidomide | 2017 |
Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
Topics: Disease-Free Survival; Humans; Immunosuppressive Agents; Infections; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasms, Second Primary; Neutropenia; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Risk; Severity of Illness Index; Survival Analysis; Survival Rate; Thalidomide; Thromboembolism | 2016 |
Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis.
Topics: Antineoplastic Agents; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Induction Chemotherapy; Infections; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Proteasome Inhibitors; Randomized Controlled Trials as Topic; Risk; Thalidomide | 2016 |
Management of the adverse effects of lenalidomide in multiple myeloma.
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Dose-Response Relationship, Drug; Gastrointestinal Diseases; Humans; Infections; Lenalidomide; Multiple Myeloma; Neutropenia; Practice Guidelines as Topic; Renal Insufficiency; Thalidomide; Thrombocytopenia; Treatment Outcome; Venous Thromboembolism | 2011 |
5 trial(s) available for lenalidomide and Infection
| Article | Year |
|---|---|
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Frail Elderly; Frailty; Hematologic Diseases; Humans; Incidence; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Progression-Free Survival; Recurrence; Republic of Korea; Thalidomide | 2020 |
Low frequency of CD3
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD4 Antigens; Dexamethasone; Female; Humans; Infections; Lenalidomide; Lymphocyte Count; Male; Middle Aged; Multiple Myeloma; NK Cell Lectin-Like Receptor Subfamily B; Recurrence; Risk Factors | 2018 |
Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Infections; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Rituximab; Salvage Therapy; Thalidomide | 2016 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Infections; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Remission Induction; Thalidomide; Treatment Outcome | 2017 |
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fever; Humans; Immunologic Factors; Infections; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Recurrence; Rituximab; Salvage Therapy; Thalidomide; Time Factors; Treatment Outcome | 2013 |
2 other study(ies) available for lenalidomide and Infection
| Article | Year |
|---|---|
Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Disease Progression; Febrile Neutropenia; Female; Humans; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Renal Insufficiency; Thrombosis | 2018 |
Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations.
Topics: Cohort Studies; Humans; Infections; Lenalidomide; Multiple Myeloma; Thalidomide | 2012 |